|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5288512A
(en)
|
1987-12-15 |
1994-02-22 |
The Procter & Gamble Company |
Reduced calorie fats made from triglycerides containing medium and long chain fatty acids
|
|
NL8800756A
(nl)
|
1988-03-25 |
1989-10-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Genetisch gemanipuleerde plantecellen en planten, alsmede daarvoor bruikbaar recombinant dna.
|
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
|
US5457189A
(en)
|
1989-12-04 |
1995-10-10 |
Isis Pharmaceuticals |
Antisense oligonucleotide inhibition of papillomavirus
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
FI924964A0
(fi)
|
1990-05-04 |
1992-11-03 |
Isis Pharmaceuticals Inc |
Modulering av genexpression genom stoerande inverkan pao sekundaerstrukturen hos rna
|
|
IE66205B1
(en)
|
1990-06-14 |
1995-12-13 |
Paul A Bartlett |
Polypeptide analogs
|
|
US5650489A
(en)
|
1990-07-02 |
1997-07-22 |
The Arizona Board Of Regents |
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
IE913929A1
(en)
|
1990-11-13 |
1992-05-20 |
Immunex Corp |
Bifunctional selectable fusion genes
|
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5474796A
(en)
|
1991-09-04 |
1995-12-12 |
Protogene Laboratories, Inc. |
Method and apparatus for conducting an array of chemical reactions on a support surface
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
EP0538194B1
(de)
|
1991-10-17 |
1997-06-04 |
Novartis AG |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5605662A
(en)
|
1993-11-01 |
1997-02-25 |
Nanogen, Inc. |
Active programmable electronic devices for molecular biological analysis and diagnostics
|
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
|
IL101600A
(en)
|
1992-04-15 |
2000-02-29 |
Yissum Res Dev Co |
Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
|
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
ATE223485T1
(de)
|
1992-10-15 |
2002-09-15 |
Toray Industries |
Verfahren zur herstellung von rekombinant mhcii protein in mikroorganismen
|
|
DE69435005T2
(de)
|
1993-05-11 |
2008-04-17 |
The University Of North Carolina At Chapel Hill |
Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
|
|
FR2705361B1
(fr)
*
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
AU6953394A
(en)
|
1993-05-21 |
1994-12-20 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
ATE247128T1
(de)
|
1993-09-03 |
2003-08-15 |
Isis Pharmaceuticals Inc |
Aminoderivatisierte nukleoside und oligonukleoside
|
|
US5491084A
(en)
|
1993-09-10 |
1996-02-13 |
The Trustees Of Columbia University In The City Of New York |
Uses of green-fluorescent protein
|
|
EP0734436B1
(en)
|
1993-11-30 |
1999-04-14 |
McGILL UNIVERSITY |
Inhibition of dna methyltransferase
|
|
US5908779A
(en)
|
1993-12-01 |
1999-06-01 |
University Of Connecticut |
Targeted RNA degradation using nuclear antisense RNA
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
US5593853A
(en)
|
1994-02-09 |
1997-01-14 |
Martek Corporation |
Generation and screening of synthetic drug libraries
|
|
EP0745134A1
(en)
|
1994-02-22 |
1996-12-04 |
Danafarber Cancer Institute |
Nucleic acid delivery system, method of synthesis and uses thereof
|
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
|
US5902880A
(en)
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
US6015880A
(en)
|
1994-03-16 |
2000-01-18 |
California Institute Of Technology |
Method and substrate for performing multiple sequential reactions on a matrix
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5525735A
(en)
|
1994-06-22 |
1996-06-11 |
Affymax Technologies Nv |
Methods for synthesizing diverse collections of pyrrolidine compounds
|
|
US5549974A
(en)
|
1994-06-23 |
1996-08-27 |
Affymax Technologies Nv |
Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
|
DE19502912A1
(de)
|
1995-01-31 |
1996-08-01 |
Hoechst Ag |
G-Cap Stabilisierte Oligonucleotide
|
|
IT1275862B1
(it)
|
1995-03-03 |
1997-10-24 |
Consiglio Nazionale Ricerche |
Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
|
|
IT1276642B1
(it)
|
1995-03-03 |
1997-11-03 |
Consiglio Nazionale Ricerche |
Trascritto antisenso presente in linfociti b ed oligodeossinucleotidi sintetici utili per inibirne l'azione
|
|
US5739311A
(en)
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases
|
|
US5569588A
(en)
|
1995-08-09 |
1996-10-29 |
The Regents Of The University Of California |
Methods for drug screening
|
|
NZ331217A
(en)
|
1996-02-14 |
2000-02-28 |
Novartis Ag |
Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
|
|
DE69724241T2
(de)
|
1996-03-14 |
2004-06-09 |
Genentech, Inc., South San Francisco |
Gdnf-rezeptor und dessen verwendung
|
|
CA2251945A1
(en)
|
1996-04-17 |
1997-10-23 |
Aronex Pharmaceuticals, Inc. |
Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
|
|
US5786213A
(en)
|
1996-04-18 |
1998-07-28 |
Board Of Regents, The University Of Texas System |
Inhibition of endogenous gastrin expression for treatment of colorectal cancer
|
|
US5756710A
(en)
|
1996-06-05 |
1998-05-26 |
The Trustees Of Columbia University In City Of New York |
Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof
|
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
|
US7235653B2
(en)
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6013786A
(en)
|
1997-08-22 |
2000-01-11 |
Hybridon, Inc. |
MDM2-specific antisense oligonucleotides
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
JP4236812B2
(ja)
|
1997-09-12 |
2009-03-11 |
エクシコン エ／エス |
オリゴヌクレオチド類似体
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US6034883A
(en)
|
1998-01-29 |
2000-03-07 |
Tinney; Charles E. |
Solid state director for beams
|
|
US6175409B1
(en)
|
1999-04-02 |
2001-01-16 |
Symyx Technologies, Inc. |
Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers
|
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
|
US6221587B1
(en)
|
1998-05-12 |
2001-04-24 |
Isis Pharmceuticals, Inc. |
Identification of molecular interaction sites in RNA for novel drug discovery
|
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
|
JP2002516256A
(ja)
|
1998-05-26 |
2002-06-04 |
アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド |
二環式糖成分を有する新規ヌクレオシド
|
|
US6100090A
(en)
|
1999-06-25 |
2000-08-08 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of PI3K p85 expression
|
|
US20030139359A1
(en)
|
2001-12-04 |
2003-07-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of phospholipid scramblase 3 expression
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6821724B1
(en)
*
|
1998-09-17 |
2004-11-23 |
Affymetrix, Inc. |
Methods of genetic analysis using nucleic acid arrays
|
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6376541B1
(en)
|
1998-11-06 |
2002-04-23 |
Alcon Manufacturing, Ltd. |
Upregulation of endogenous prostaglandins to lower intraocular pressure
|
|
US5985663A
(en)
|
1998-11-25 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of interleukin-15 expression
|
|
DK1146908T3
(da)
|
1999-01-27 |
2005-10-10 |
Becker David Dr |
Formuleringer omfattende antisense-nukleotider mod connexiner
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
JP4785252B2
(ja)
|
1999-02-26 |
2011-10-05 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
Ｔｒｐｍ−２アンチセンス療法
|
|
DE60035163T2
(de)
|
1999-03-15 |
2008-02-21 |
University Of British Columbia, Vancouver |
Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
|
|
US20040137423A1
(en)
|
1999-03-15 |
2004-07-15 |
Hayden Michael R. |
Compositions and methods for modulating HDL cholesterol and triglyceride levels
|
|
HK1048339A1
(zh)
|
1999-03-18 |
2003-03-28 |
埃克西库恩公司 |
利用特异性lna引物检测基因突变
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
DE60029314T2
(de)
|
1999-03-24 |
2007-07-12 |
Exiqon A/S |
Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
KR20050044812A
(ko)
|
1999-03-26 |
2005-05-12 |
아벤티스 파마슈티칼스 인크. |
Ｌｉｐｇ의 발현을 저하시키고 고밀도 지단백질(ｈｄｌ)콜레스테롤 및 아포지단백질 ａｉ의 수준을 증가시키는조성물
|
|
DE60038011T2
(de)
|
1999-04-08 |
2009-02-12 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
|
|
US6977295B2
(en)
|
1999-04-21 |
2005-12-20 |
Invitrogen Corporation |
Locked nucleic acid hybrids and methods of use
|
|
US7053207B2
(en)
|
1999-05-04 |
2006-05-30 |
Exiqon A/S |
L-ribo-LNA analogues
|
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
|
DE19925073C2
(de)
|
1999-06-01 |
2001-07-19 |
Stefan Weiss |
Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
CA2383871A1
(en)
|
1999-06-25 |
2001-01-04 |
Genset S.A. |
A novel bap28 gene and protein
|
|
US20040006031A1
(en)
|
2002-07-02 |
2004-01-08 |
Isis Pharmaceuticals Inc. |
Antisense modulation of HMG-CoA reductase expression
|
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
|
EP1218411A4
(en)
|
1999-09-20 |
2004-09-01 |
Millennium Pharm Inc |
SECRETED PROTEINS AND THEIR USES
|
|
NZ517929A
(en)
*
|
1999-09-25 |
2004-02-27 |
Univ Iowa Res Found |
Immunostimulatory nucleic acids
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US6528262B1
(en)
|
1999-10-06 |
2003-03-04 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
|
US6986988B2
(en)
|
1999-10-06 |
2006-01-17 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
|
DE1252330T1
(de)
*
|
1999-11-26 |
2003-11-27 |
Mcgill University, Montreal |
Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
|
|
WO2001051630A1
(en)
|
2000-01-07 |
2001-07-19 |
Baylor University |
Antisense compositions and methods
|
|
US7087589B2
(en)
|
2000-01-14 |
2006-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methanocarba cycloakyl nucleoside analogues
|
|
US6303374B1
(en)
|
2000-01-18 |
2001-10-16 |
Isis Pharmaceuticals Inc. |
Antisense modulation of caspase 3 expression
|
|
JP2001247459A
(ja)
|
2000-03-03 |
2001-09-11 |
Oakland Uniservices Ltd |
癌の組み合わせ療法
|
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
|
EP1268768A2
(en)
|
2000-03-27 |
2003-01-02 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
|
EP1268856A2
(de)
*
|
2000-04-07 |
2003-01-02 |
Epigenomics AG |
Detektion von snp's und cytosin-methylierungen
|
|
US7402434B2
(en)
|
2000-05-08 |
2008-07-22 |
Newman Stuart A |
Splice choice antagonists as therapeutic agents
|
|
JP2001352987A
(ja)
*
|
2000-06-13 |
2001-12-25 |
Japan Science & Technology Corp |
ナトリウムチャンネルｓｃｎ１ａ
|
|
JP2004530420A
(ja)
|
2000-06-29 |
2004-10-07 |
ファーマ パシフィック プロプライエタリー リミテッド |
インターフェロン−α誘導性遺伝子
|
|
WO2002009700A1
(en)
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Cancer treatment by combination therapy
|
|
US7053199B2
(en)
|
2000-08-29 |
2006-05-30 |
Takeshi Imanishi |
Nucleoside analogs and oligonucleotide derivatives containing these analogs
|
|
AU2001295531A1
(en)
|
2000-09-02 |
2002-03-13 |
Grünenthal GmbH |
Antisense oligonucleotides against vanilloid receptor 1
|
|
US6444464B1
(en)
|
2000-09-08 |
2002-09-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of E2F transcription factor 2 expression
|
|
EP1319014A1
(en)
|
2000-09-20 |
2003-06-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of flip-c expression
|
|
EP1325121A2
(en)
|
2000-10-13 |
2003-07-09 |
Institut de Cardiologie de Montreal |
Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
|
|
US20030228618A1
(en)
|
2000-11-24 |
2003-12-11 |
Erez Levanon |
Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
|
|
US20050222029A1
(en)
|
2001-01-04 |
2005-10-06 |
Myriad Genetics, Incorporated |
Compositions and methods for treating diseases
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US20020147165A1
(en)
|
2001-02-22 |
2002-10-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of calreticulin expression
|
|
JP2004531238A
(ja)
|
2001-02-26 |
2004-10-14 |
ファーマ パシフィック プロプライエタリー リミテッド |
インターフェロン−アルファ誘導遺伝子
|
|
CA2443968A1
(en)
*
|
2001-04-12 |
2002-10-24 |
Imperial College Innovations Limited |
Diagnosis and treatment of cancer: i
|
|
WO2002085309A2
(en)
*
|
2001-04-24 |
2002-10-31 |
Epigenesis Pharmaceuticals, Inc. |
Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
|
|
AUPR497101A0
(en)
|
2001-05-14 |
2001-06-07 |
Queensland University Of Technology |
Polynucleotides and polypeptides linked to cancer and/or tumorigenesi
|
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
|
US20060122789A1
(en)
*
|
2001-05-30 |
2006-06-08 |
Feldmann Richard J |
Symmetry relationships between pairs of connectrons
|
|
US7053195B1
(en)
|
2001-06-12 |
2006-05-30 |
Syngenta Participatious Ag |
Locked nucleic acid containing heteropolymers and related methods
|
|
IL159756A0
(en)
|
2001-07-12 |
2004-06-20 |
Univ Massachusetts |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
|
US7153954B2
(en)
|
2001-07-12 |
2006-12-26 |
Santaris Pharma A/S |
Method for preparation of LNA phosphoramidites
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
CA2459347C
(en)
|
2001-09-04 |
2012-10-09 |
Exiqon A/S |
Locked nucleic acid (lna) compositions and uses thereof
|
|
US20040214766A1
(en)
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
|
OA12667A
(en)
|
2001-10-10 |
2006-06-19 |
Nestle Sa |
Coffee plant with reduced alpha-D-galactosidase activity.
|
|
AR037699A1
(es)
|
2001-12-04 |
2004-12-01 |
Monsanto Technology Llc |
Maiz transgenico con fenotipo mejorado
|
|
US7125982B1
(en)
|
2001-12-05 |
2006-10-24 |
Frayne Consultants |
Microbial production of nuclease resistant DNA, RNA, and oligo mixtures
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
CA2365811A1
(en)
|
2001-12-21 |
2003-06-21 |
Institut De Cardiologie |
A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
|
|
KR20030056538A
(ko)
|
2001-12-28 |
2003-07-04 |
주식회사 웰진 |
리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
|
|
WO2003066893A1
(de)
*
|
2002-02-04 |
2003-08-14 |
Vermicon Ag |
Verfahren zum spezifischen schnellnachweis pathogener lebensmittelrelevanter bakterien
|
|
US20030191075A1
(en)
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
|
US20050143357A1
(en)
|
2002-02-25 |
2005-06-30 |
Ake Pousette |
Vitamin d upregulated protein 1 (vdup-) methods and uses thereof
|
|
AU2003225701A1
(en)
|
2002-03-08 |
2003-09-22 |
Glen Research Corporation |
Fluorescent nitrogenous base and nucleosides incorporating same
|
|
GB2386836B
(en)
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
|
US7169916B2
(en)
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
|
US20050215504A1
(en)
|
2002-04-02 |
2005-09-29 |
Bennett C F |
Antisense modulation of sterol regulatory element-binding protein-1 expression
|
|
AU2003225495B2
(en)
|
2002-04-05 |
2009-01-15 |
Roche Innovation Center Copenhagen A/S |
Oligomeric compounds for the modulation HIF-1alpha expression
|
|
US6808906B2
(en)
|
2002-05-08 |
2004-10-26 |
Rigel Pharmaceuticals, Inc. |
Directionally cloned random cDNA expression vector libraries, compositions and methods of use
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
WO2004016754A2
(en)
|
2002-08-14 |
2004-02-26 |
Pharmacia Corporation |
ANTISENSE MODULATION OF Nav1.3 EXPRESSION
|
|
US20040033480A1
(en)
|
2002-08-15 |
2004-02-19 |
Wong Norman C.W. |
Use of resveratrol to regulate expression of apolipoprotein A1
|
|
WO2004024079A2
(en)
|
2002-09-10 |
2004-03-25 |
The Samuel Roberts Noble Foundation, Inc. |
Methods and compositions for production of flavonoid and isoflavonoid nutraceuticals
|
|
EP1549387A1
(en)
|
2002-09-25 |
2005-07-06 |
Pharmacia Corporation |
Antisense modulation of farnesoid x receptor expression
|
|
JP2006500066A
(ja)
*
|
2002-09-25 |
2006-01-05 |
ファルマシア・コーポレーション |
ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節
|
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
|
NZ540779A
(en)
|
2002-11-01 |
2008-05-30 |
Univ Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
|
WO2004041838A1
(en)
|
2002-11-01 |
2004-05-21 |
University Of Massachusetts |
Regulation of transcription elongation factors
|
|
GB2394658A
(en)
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
|
WO2004041889A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US20060009410A1
(en)
|
2002-11-13 |
2006-01-12 |
Crooke Rosanne M |
Effects of apolipoprotein B inhibition on gene expression profiles in animals
|
|
AU2003295600A1
(en)
*
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US7250496B2
(en)
*
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
US20080318210A1
(en)
*
|
2003-08-27 |
2008-12-25 |
Rosetta Genomics |
Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
JP2007537984A
(ja)
*
|
2003-03-04 |
2007-12-27 |
ワイス |
喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
|
|
JP2004275115A
(ja)
*
|
2003-03-18 |
2004-10-07 |
Institute Of Physical & Chemical Research |
重篤な知的能力の退行を伴う難治小児てんかんにおけるｓｃｎ２ａ遺伝子の変異
|
|
AU2003901425A0
(en)
|
2003-03-27 |
2003-04-10 |
Bionomics Limited |
A diagnostic method for epilepsy
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
WO2004094636A1
(en)
|
2003-04-24 |
2004-11-04 |
Galapagos Genomics N.V. |
Effective sirna knock-down constructs
|
|
US7339051B2
(en)
|
2003-04-28 |
2008-03-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
|
|
WO2004108081A2
(en)
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
|
JP4579911B2
(ja)
|
2003-06-03 |
2010-11-10 |
アイシス・ファーマシューティカルズ・インコーポレイテッド |
スルビビン発現の調節
|
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
|
ATE459707T1
(de)
*
|
2003-06-30 |
2010-03-15 |
Dnavec Research Inc |
Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
EP2256201A3
(en)
|
2003-09-18 |
2012-07-04 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E expression
|
|
WO2005038013A1
(en)
|
2003-10-07 |
2005-04-28 |
Isis Pharmaceuticals, Inc. |
Artisense oligonucleotides optimized for kidney targeting
|
|
CA2541836A1
(en)
|
2003-10-13 |
2005-04-21 |
Bionomics Limited |
A diagnostic method for neonatal or infantile epilepsy syndromes
|
|
WO2005044981A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
WO2005045034A2
(en)
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
|
|
WO2005061710A1
(en)
|
2003-12-23 |
2005-07-07 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of bcl-2
|
|
JP4801802B2
(ja)
|
2004-01-12 |
2011-10-26 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質（ｂｍｐ）遺伝子発現を上方制御するシステムおよび方法
|
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
GB0403041D0
(en)
|
2004-02-11 |
2004-03-17 |
Milner Anne J |
Induction of apoptosis
|
|
EP1566202A1
(en)
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Use of resistin antagonists in the treatment of rheumatoid arthritis
|
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
|
US7842800B2
(en)
*
|
2004-04-02 |
2010-11-30 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
|
|
WO2005116204A1
(ja)
*
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
EP2351839A3
(en)
*
|
2004-07-02 |
2011-10-05 |
AVI BioPharma, Inc. |
Antisense antibacterial method and compound
|
|
US7297786B2
(en)
|
2004-07-09 |
2007-11-20 |
University Of Iowa Research Foundation |
RNA interference in respiratory epitheial cells
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
|
MX2007005558A
(es)
|
2004-11-09 |
2008-01-31 |
Santaris Pharma As |
Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
|
|
EP1828413A1
(en)
*
|
2004-12-24 |
2007-09-05 |
Ares Trading S.A. |
Compositions and methods for treating mental disorders
|
|
US7220549B2
(en)
|
2004-12-30 |
2007-05-22 |
Helicos Biosciences Corporation |
Stabilizing a nucleic acid for nucleic acid sequencing
|
|
EP1904630A4
(en)
*
|
2005-06-16 |
2009-10-21 |
Bionomics Ltd |
METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
|
|
WO2007002718A2
(en)
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and theraputic uses thereof
|
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
JP5111385B2
(ja)
|
2005-10-28 |
2013-01-09 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ハンチンチン遺伝子の発現を抑制するための組成物および方法
|
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
|
WO2007086990A2
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
|
AU2006339607A1
(en)
|
2005-12-02 |
2007-09-13 |
Sirtris Pharmaceuticals, Inc. |
Modulators of Cdc2-like kinases (Clks) and methods of use thereof
|
|
CN101374964B
(zh)
|
2005-12-09 |
2013-07-17 |
贝勒研究院 |
外周血液白细胞转录模式的模块水平分析
|
|
WO2007071824A1
(en)
|
2005-12-20 |
2007-06-28 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein -cholesterol (hdl-c)
|
|
CN100356377C
(zh)
|
2005-12-20 |
2007-12-19 |
无锡永中科技有限公司 |
文档显示方法
|
|
JP5713377B2
(ja)
|
2005-12-28 |
2015-05-07 |
ザ スクリプス リサーチ インスティテュート |
薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
WO2007090071A2
(en)
|
2006-01-27 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
WO2007107162A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
NZ571568A
(en)
|
2006-03-31 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
|
|
JP2009536222A
(ja)
*
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
EP1867338A1
(en)
|
2006-05-30 |
2007-12-19 |
Université Libre De Bruxelles |
Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
|
|
JP2010505897A
(ja)
*
|
2006-10-11 |
2010-02-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
インフルエンザターゲット
|
|
WO2008066672A2
(en)
|
2006-11-06 |
2008-06-05 |
Beth Israel Deaconess Medical Center |
Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases
|
|
WO2008057556A2
(en)
|
2006-11-06 |
2008-05-15 |
Beth Israel Deaconess Medical Center |
Identification and use of small molecules to modulate ese-1 transcription factor function and to treat ese-1 transcription factor associated diseases
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
ES2447840T3
(es)
|
2007-01-19 |
2014-03-13 |
Plant Bioscience Limited |
Métodos para la modulación de las vías de metilación del SIRNA y ADN dirigido por ARN
|
|
JP5205979B2
(ja)
|
2007-01-23 |
2013-06-05 |
日立電線株式会社 |
絶縁電線
|
|
US20100255117A1
(en)
|
2007-04-06 |
2010-10-07 |
The Johns Hopkins University |
Methods and compositions for the treatment of cancer
|
|
US20080293142A1
(en)
|
2007-04-19 |
2008-11-27 |
The Board Of Regents For Oklahoma State University |
Multiple shRNA Expression Vectors and Methods of Construction
|
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
|
WO2009049181A1
(en)
|
2007-10-11 |
2009-04-16 |
Vertex Pharmaceuticals Incorporated |
Amides useful as inhibitors of voltage-gated sodium channels
|
|
CN201191661Y
(zh)
|
2008-01-29 |
2009-02-04 |
富士康(昆山)电脑接插件有限公司 |
电连接器组件
|
|
WO2009143277A2
(en)
*
|
2008-05-20 |
2009-11-26 |
Intradigm Corporation |
Compositions comprising hscn9a sirna and methods of use thereof
|
|
AU2009267007B2
(en)
|
2008-07-01 |
2016-02-25 |
Monsanto Technology, Llc |
Recombinant DNA constructs and methods for modulating expression of a target gene
|
|
WO2010000656A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)
|
|
CN102239260B
(zh)
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
US8606289B2
(en)
|
2008-11-10 |
2013-12-10 |
Qualcomm Incorporated |
Power headroom-sensitive scheduling
|
|
JP2012509306A
(ja)
|
2008-11-22 |
2012-04-19 |
ザ ユニバーシティ オブ ブリストル |
ＶＥＧＦｘｘｘｂの新規な使用
|
|
ES2600781T3
(es)
*
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
ES2629630T3
(es)
*
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
|
US20110237649A1
(en)
*
|
2008-12-04 |
2011-09-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
|
US20130036482A1
(en)
|
2010-01-29 |
2013-02-07 |
National University Corporation Okayama University |
Method for assessment of potential for development of dravet syndrome and use thereof
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
WO2012002460A1
(ja)
|
2010-06-29 |
2012-01-05 |
公立大学法人名古屋市立大学 |
イオンチャネルに作用する化合物のスクリーニング用材料及びその利用
|